Follow-up of the Inspiron EVO drug-eluting stent for complex coronary artery blockages
Follows adults with coronary artery disease treated with the Inspiron EVO drug-eluting stent.
Plain-language title generated from the registry record
Registry title: Brazilian Prospective Registry of the Inspiron EVO Drug-Eluting Stent in Complex Coronary Lesions
Key facts
- Where
- Porto Alegre, BrazilSee the site
Where in Brazil
- Pontificia Universidade Catolica do Rio Grande do Sul (PUCRS)Porto Alegre, BrazilTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Scitech Produtos Medicos SA
- Trial code
- NCT07491107
- Record updated
- 2 October 2026
- Original description
The objective is to evaluate the efficacy and safety of the Inspiron™ EVO drug-eluting stent in complex coronary lesions in a real-world population. Patients with symptomatic ischemic heart disease due to lesions in native coronary arteries and restenotic lesions will be treated with the Inspiron™ EVO drug-eluting stent.Read full original descriptionShow less
National Prospective Registry of the Inspiron EVO Drug-Eluting Stent in Complex Coronary Lesions
The objective is to evaluate the efficacy and safety of the Inspiron™ EVO drug-eluting stent in complex coronary lesions in a real-world population. Patients with symptomatic ischemic heart disease due to lesions in native coronary arteries and restenotic lesions will be treated with the Inspiron™ EVO drug-eluting stent.
Inclusion: Individuals aged 18 years or older presenting with complex coronary lesions requiring percutaneous coronary intervention (PCI); Individuals who provide consent and are willing to comply with the follow-up protocol; Individuals who received treatment with the Inspiron™ EVO Stent; Individuals with lesions ≥ 30 mm in length (Subprotocol 1); Individuals with significantly calcified coronary lesions (moderate to severe according to the ACC/AHA classification B1, B2, or C), with or without indication for lesion preparation techniques (Subprotocol 2); Individuals with multivessel coronary artery disease (≥2 affected coronary vessels, with at least one vessel of small diameter ≤2.5 mm) (Subprotocol 3); Individuals included in Subprotocol 1, 2, or 3. The evaluated segment must be accessible to the IVUS (Intravascular Ultrasound) catheter (Subprotocol 4).
Exclusion: Contraindication to the use of a drug-eluting stent; Lesions in saphenous vein grafts or internal mammary grafts; Individuals who were treated during the index procedure with any stent other than the Inspiron™ EVO Stent.